Affiliation:
1. Saitama Medical University
Abstract
Abstract
Background
Biomarkers for predicting the outcome of ipilimumab plus nivolumab (Nivo-Ipi) treatment in cancer patients have not been identified. Herein, we investigated the prognostic significance of inflammatory and nutritional markers in patients with advanced non-small cell lung cancer (NSCLC) receiving Nivo-Ipi.
Methods
Our study retrospectively analyzed 101 patients with advanced NSCLC who received Nivo-Ipi at a single institution. Inflammatory and nutritional indices were correlated with patient outcomes and included the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI), and Glasgow prognostic score (GPS).
Results
The NLR significantly correlated with the PLR, SII, PNI, ALI, and GPS. Regarding therapeutic efficacy, the NLR, SII, and PNI predicted a partial response, and all indices predicted progressive disease. In subgroup analyses, the SII, PNI, and ALI predicted the outcome of patients with adenocarcinoma, whereas only the PNI predicted the outcome of patients without adenocarcinoma. The PNI and SII were the most useful indices in patients with a programmed death ligand-1 expression level of < 1% and ≥ 1%, respectively.
Conclusion
The NLR, PLR, SII, PNI, ALI, and GPS were significantly associated with the outcome of Nivo-Ipi treatment in patients with NSCLC. The PNI was the most suitable marker regardless of histological type. The SII and PNI were the most promising markers for patients with and without PD-L1 expression, respectively.
Publisher
Research Square Platform LLC
Reference21 articles.
1. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon EB;N Engl J Med,2015
2. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227;Brahmer JR;J Clin Oncol,2023
3. Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al (2023) First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. Eur J Cancer. 2023 Apr;183:174–187.
4. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study;Johnson ML;J Clin Oncol,2023
5. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma;Wolchok JD;N Engl J Med.,2017